Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Tiziana Life Sciences PLC    TILS   GB00BKWNZY55

TIZIANA LIFE SCIENCES PLC

(TILS)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

ASCO Abstract 298561: Phase 2a Safety and Efficacy of Milciclib, a Pan-Cyclin Dependent Kinase Inhibitor, in Unresectable, Sorafenib-Refractory or -Intolerant Hepatocellular Carcinoma Patients

share with twitter share with LinkedIn share with facebook
05/14/2020 | 10:10am EDT

Title:

Phase 2a Safety and Efficacy of Milciclib, a Pan-Cyclin Dependent Kinase Inhibitor, in Unresectable, Sorafenib-Refractory or -Intolerant Hepatocellular Carcinoma Patients.

Authors and Affiliations:

Erica Villa, Fabio Piscaglia, Rabit Geva, George Dalecos, George Papatheodoridis, Marina Ciomei, Christina Davite, Patrizia Crivori, Vaseem Palejwala, Jules Jacob, Fayez Hamzeh, Kunwar Shailubhai, Armando Santoro, Angelo Sangiovanni; Policlinico di Modena, Modena, Italy; University of Bologna, Bologna, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel; 5General University Hospital of Larissa, Thessaly, Greece; Laiko General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece; Nerviano Medical Sciences, Nerviano, Italy; Clinical Organization for Strategies and Solutions (CLIOSS), NMS Group, Nerviano, Italy; Clinical Organization for Strategies and Solutions (CLIOSS), NMS Group, Nerviano, Italy, Nerviano, Italy; TIziana Life Sceinces, Doylestown, PA; jjacob@tizianalifesciences.com, Doylestown, PA; Humanitas Cancer Center, Humanitas University, Milan, Italy; Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

Background:

Current hepatocellular carcinoma (HCC) therapeutics, tyrosine kinase inhibitors (TKI) and checkpoint inhibitors (CI), provide limited improvement in overall survival, suggesting the need to identify drugs with broad-spectrum mechanisms of action, used alone or in combination with a TKI or CI. Milciclib, a pan cyclin dependent kinase inhibitor, exhibited anti-cancer activity in refractory solid malignancy patients. The primary objective of this trial was to evaluate safety and tolerability of milciclib in sorafenib-refractory or intolerant advanced HCC patients.

Methods:

Single arm and multi-center study in advanced HCC patients was conducted in Italy, Greece and Israel. Milciclib was administered orally for up to 6 cycles. Each cycle consisted of 100mg milciclib daily for 4d on/3d off/week for 4 weeks. Safety assessment was the primary endpoint and secondary endpoints included progression free survival (PFS), time to progression (TTP) and clinical benefit rate (CBR).

Results:

A total of 31 patients were enrolled and 28 were evaluable for efficacy, of which 14 (50%) completed 6-months of treatment. Milciclib was well-tolerated with manageable toxicities. Eighteen of 31 treated patients had drug-related adverse events (AEs) with most frequent (≥5%) occurrence of drug-related diarrhea, nausea, asthenia, fatigue, retinal hemorrhage, rash and myalgia. No drug-related deaths were recorded. Nine of 14 patients (64%) continued treatment under Compassionate Use after study completion. Seven patients received milciclib until 9, 9, 10, 11, 13, 13 and 16 months. The remaining 2 patients are in the 16th month of treatment. Clinical response to treatment, assessed by mRECIST (independent radiological review), is shown in the Table. Both median TTP and PFS were 5.9 months.

Parameter n % 95%CI LL-UL

Objective Response (CR+PR) 1 3.6 0.1-18.4

CBR (CR+PR+SD) 17 60.7 40.6-78.5

Partial Response (PR)* 1 3.6

Stable Disease (SD) 16 57.1

Progressive Disease 10 35.7

Missing 1 3.6

*Unconfirmed

Conclusions:

Milciclib, acting via a new mechanism, was safe, well-tolerated and met primary and secondary endpoints with 61% CBR. These promising clinical data warrant further evaluation of milciclib.

Disclaimer

Tiziana Life Sciences plc published this content on 14 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 May 2020 14:09:06 UTC

share with twitter share with LinkedIn share with facebook
Latest news on TIZIANA LIFE SCIENCES PLC
06/29TIZIANA LIFE SCIENCES : Announces Agreement with STC Biologics for GMP Manufactu..
AQ
06/29TIZIANA LIFE SCIENCES : Agreement with STC Biologics for GMP Manufacturing of an..
PU
06/19TIZIANA LIFE SCIENCES : Patent Granted for Oral Administration
PU
06/18TIZIANA LIFE SCIENCES : Directorate Change
AQ
06/18TIZIANA LIFE SCIENCES : 20 F - Annual Report for the year ended 31 December 2019
PU
06/18TIZIANA LIFE SCIENCES : Final Results for the Year Ended 31 December 2019
PU
06/18TIZIANA LIFE SCIENCES : Annual Report for the year ended 31 December 2019
PU
06/12TIZIANA LIFE SCIENCES : Extension of At the Market Sales Agreement
PU
06/01TIZIANA LIFE SCIENCES : Appointment of BrokerAppointment of Broker
PU
05/25TIZIANA LIFE SCIENCES : Lifesciences Announces Intention to Demerge Its StemPrin..
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 183 M 228 M 228 M
EV / Sales 2019
Capi. / Sales 2020 -
Nbr of Employees 8
Free-Float -
Chart TIZIANA LIFE SCIENCES PLC
Duration : Period :
Tiziana Life Sciences PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TIZIANA LIFE SCIENCES PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 500,00 GBX
Last Close Price 110,00 GBX
Spread / Highest target 355%
Spread / Average Target 355%
Spread / Lowest Target 355%
Managers
NameTitle
Kunwar Shailubhai CEO, Executive Director & Chief Scientific Officer
Gabriele Marco Antonio Cerrone Executive Chairman
Tiziano Lazzaretti Chief Financial Officer
Jules S. Jacob Senior Director-Non-Clinical Development
Vaseem A. Palejwala Director-Clinical Operations